Please login to the form below

Not currently logged in
Email:
Password:

Seattle Genetics

This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.

Immunomedics craters after FDA rejects breast cancer ADC

Immunomedics craters after FDA rejects breast cancer ADC

The drug was the subject of an investor revolt when the biotech’s former management tried to license it to Seattle Genetics in 2017, which ultimately claimed the scalps of Immunomedics’

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

  • Bluebird and Celgene BCMA CAR-T kicks off ASCO Bluebird and Celgene BCMA CAR-T kicks off ASCO

    to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    Seattle Genetics has won FDA approval for Adcetris as a first-line treatment for advanced Hodgkin’s lymphoma, which it believes could help unlock blockbuster sales for the drug in the ... Seattle has since turned its attention to its own TNBC candidate

  • Takeda bags EU approval for Adcetris in lymphoma Takeda bags EU approval for Adcetris in lymphoma

    Originally developed by Seattle Genetics, Adcetris has been on the market for just over six years and has seen sales grow steadily to around $600m last year, driven by a stream ... There are more new indications on the way, and Takeda and Seattle

  • Seattle Genetics' Adcetris earns FDA priority review status Seattle Genetics' Adcetris earns FDA priority review status

    Seattle Genetics’ Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the lymphoma drug priority review status. ... Clay Siegall, president and chief executive officer of Seattle Genetics, said: “We recently

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with

  • Deal Watch March 2017 Deal Watch March 2017

    In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Pharma deals in June 2015 Pharma deals in June 2015

    NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics